Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Stomatitis|Head and Neck Cancer|Mucositis|Pneumonia, Ventilator-Associated
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CDR0000068810 | P3 |
Unknown status |
Stomatitis|Head and Neck Cancer|Mucositis |
None |
|
| NCT00118781 | P3 |
Terminated |
Pneumonia, Ventilator-Associated |
None |